• Three abstracts involving Oncoceutics’ lead clinical compound, ONC201, will be presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on October 28th and 29th, 2017. ONC201 is the first Dopamine Receptor 2 (DRD2) antagonist for clinic oncology and the first imipridone to enter the clinic, with 8 active clinical trials in specific types of advanced cancer.

    Two abstracts report molecular explanations for how ONC201 interacts with DRD2, its novel binding target, and interferes with signaling pathways in cancer cells in a safe and effective way that differentiates it from other therapeutics. The third abstracts describes how DRD2 and other members of the dopamine receptor family can be utilized to generate in a predictive biomarker signature for ONC201 that allows investigators to predict which specific tumors are more likely undergo a strong response to ONC201. While the biomarker signature was discovered and validated in laboratory studies, this signature also appears to be present in tumor samples of patients who have experienced favorable clinical outcomes while taking ONC201. Together, these abstracts provide molecular information that explains the unique profile of ONC201 that has been observed in preclinical studies and clinical trials, and provide the tools to hone future clinical trials with ONC201 to enrich for potentially responsive patients.

    Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses
    October 28, 2017, 12:30 – 4:00 PM

    Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology
    October 29, 2017, 12:30 – 4:00 PM

    The third abstract comes from the laboratory of Dr. Stanley Lipkowitz at the National Institutes of Health. Dr. Lipkowitz and his lab present on further elucidation of the ONC201 mechanism of action, specifically the impact ONC201’s effects on the integrated stress response have on mitochondria in breast cancer cells.

    ONC201 kills breast cancer cells by targeting mitochondria
    October 29, 2017, 12:30 – 4:00 PM